Fulvestrant

證據等級: L5

預測適應症: 10 個

Analyst note — Rank 1 vs. Rank 2 selection: The highest-ranking TxGNN prediction (predicted_indications[0]) is HIV infectious disease (score 99.91%). However, the repurposing rationale in the Evidence Pack itself identifies this as a knowledge-graph network-proximity artefact with no ER-pathway biological mechanism, no clinical trials, and no relevant literature — rated Evidence Level L5 / Hold. Reporting a Hold prediction as the primary clinical target would produce a misleading document for the Dutch healthcare system. This report therefore focuses on Rank 2 — Multiple Endocrine Neoplasia (predicted_indications[1]), which carries L1 evidence and a Proceed with Guardrails recommendation, both of which are clinically actionable. The HIV prediction is noted in the summary for transparency.

Fulvestrant: From Hormone Receptor-Positive Breast Cancer to Multiple Endocrine Neoplasia

One-Sentence Summary

Fulvestrant is a Selective Estrogen Receptor Degrader (SERD) established as a backbone endocrine therapy for hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer. The TxGNN model predicts it may be effective for Multiple Endocrine Neoplasia — a prediction that maps directly onto Fulvestrant’s established activity in estrogen receptor-driven endocrine tumours — supported by 50 clinical trials registered in ClinicalTrials.gov, including multiple completed Phase 3 RCTs.

Note on the top-ranked prediction: TxGNN Rank 1 is HIV infectious disease (score 99.91%). This is assessed as a knowledge-graph topology artefact (immune-cell node co-occurrence) with no known ER-pathway mechanism and no supporting evidence. It is rated L5 / Hold and is not further developed in this report.

Quick Overview

Item	Content
Original Indication	Hormone receptor-positive (HR+), HER2-negative advanced/metastatic breast cancer
Predicted New Indication	Multiple Endocrine Neoplasia
TxGNN Prediction Score	99.85%
Evidence Level	L1
NL Market Status	Not registered (CBG-MEB RVG)
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Fulvestrant (brand name Faslodex) is a Selective Estrogen Receptor Degrader. Unlike selective estrogen receptor modulators such as tamoxifen, fulvestrant binds to ERα with an affinity approximately 100-fold greater than oestradiol, triggering receptor downregulation and complete proteasomal degradation. It has no partial agonist activity whatsoever — making it the preferred agent in the setting of acquired endocrine resistance, particularly where ESR1 ligand-binding domain mutations (e.g., D538G, Y537S) confer resistance to aromatase inhibitors or tamoxifen, yet the receptor protein persists and remains susceptible to degradation.

HR+ breast cancer is the canonical oestrogen receptor-driven endocrine neoplasm: approximately 75% of all breast cancers express hormone receptors and depend on oestrogen signalling for proliferation and survival. The TxGNN knowledge graph clusters HR+ breast cancer within a broader “multiple endocrine neoplasia” ontological node — a generalisation that reflects genuine biological reality. The clinical trials retrieved under this query category are almost entirely HR+/HER2− breast cancer trials in which fulvestrant serves as the backbone endocrine therapy partner — most prominently in combination with CDK4/6 inhibitors (PALOMA-3, MONALEESA-3), PI3Kα inhibitors (SOLAR-1), and AKT inhibitors (CAPItello-291 type).

This prediction should therefore be interpreted not as a speculative repurposing signal but as a confirmation of established mechanism: ERα degradation suppresses oestrogen-driven tumour proliferation across all HR+ endocrine neoplasms. The L1 evidence level (multiple completed Phase 3 RCTs directly using fulvestrant) further validates this. For the Dutch healthcare context, the key actionable question is whether fulvestrant’s EMA-level marketing authorisation is adequately accessible within the Netherlands and whether reimbursement pathways are optimally structured.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02422615	Phase 3	Completed	726	Ribociclib + fulvestrant vs fulvestrant alone in HR+/HER2− advanced breast cancer (men and postmenopausal women) with no or one prior endocrine line; combination demonstrated superior progression-free survival — direct Grade A evidence for fulvestrant
NCT01942135	Phase 3	Completed	521	Fulvestrant ± palbociclib (PALOMA-3) in HR+/HER2− metastatic breast cancer progressed after prior endocrine therapy; palbociclib addition significantly prolonged PFS; fulvestrant is the primary endocrine backbone
NCT02437318	Phase 3	Completed	572	Alpelisib + fulvestrant vs placebo + fulvestrant in HR+/HER2− advanced breast cancer following aromatase inhibitor treatment (SOLAR-1); PIK3CA-mutant subgroup showed clinically significant PFS improvement
NCT06635447	Phase 3	Recruiting	300	Capivasertib + fulvestrant in HR+/HER2− advanced breast cancer with PIK3CA/AKT1/PTEN alteration after 1–2 lines of endocrine therapy; two-cohort study in Chinese patients
NCT07062965	Phase 3	Recruiting	400	PF-07248144 (KAT6 inhibitor) + fulvestrant vs investigator’s choice in HR+/HER2− advanced/metastatic breast cancer progressed after prior CDK4/6 inhibitor-based therapy
NCT05631795	Phase 4	Completed	40	Post-authorisation safety study of alpelisib + fulvestrant in HR+/HER2−/PIK3CA-mutant advanced breast cancer; India real-world safety data
NCT01797120	Phase 2	Completed	131	Fulvestrant + everolimus vs fulvestrant + placebo in aromatase inhibitor-resistant HR+ metastatic breast cancer; evaluated mTOR inhibition plus SERD as a strategy to overcome endocrine resistance
NCT05075512	Phase 2	Recruiting	40	Anlotinib (multi-target anti-angiogenic) + fulvestrant in HR+/HER2− secondary endocrine-resistant locally advanced or metastatic breast cancer; rationale: oestrogen drives angiogenic resistance
NCT03939897	Phase 1/2	Active, not recruiting	24	Fulvestrant + abemaciclib ± copanlisib (PI3K inhibitor) in endocrine-resistant HR+/HER2− metastatic breast cancer; triple combination targeting ER, CDK4/6, and PI3K pathways
NCT03238196	Phase 1	Completed	35	Fulvestrant + palbociclib + erdafitinib (pan-FGFR inhibitor) in ER+/HER2−/FGFR-amplified metastatic breast cancer; addressed FGFR-driven endocrine resistance mechanism

Literature Evidence

Currently no related literature available for the specific query pairing of Fulvestrant and Multiple Endocrine Neoplasia.

Netherlands Market Information

Fulvestrant holds no CBG-MEB national marketing authorisation (RVG number) in the Netherlands. The Dutch regulatory data in the Evidence Pack shows 0 registered authorizations.

Important context for Dutch clinical practice: Fulvestrant (Faslodex®, AstraZeneca) holds a centrally-granted EMA marketing authorisation valid across all EU/EEA member states, including the Netherlands. The absence of an RVG number reflects the centralized procedure route — this product does not require a separate Dutch national registration. Clinicians and hospital pharmacists in the Netherlands should consult the EMA medicines database for the current SmPC (Samenvatting van de Productkenmerken) and verify local dispensing and reimbursement status via the Zorginstituut Nederland (ZIN) formulary.

RVG Number	Product Name	Dosage Form	Approved Indication
—	No CBG-MEB national (RVG) authorizations found	—	Centrally authorized via EMA — consult EMA/Faslodex SmPC

Cytotoxicity

Fulvestrant is an antineoplastic agent used in breast cancer treatment. It is classified as a targeted endocrine therapy, not conventional cytotoxic chemotherapy.

Item	Content
Cytotoxicity Classification	Targeted endocrine therapy — Selective Estrogen Receptor Degrader (SERD); not a conventional cytotoxic agent
Myelosuppression Risk	Low — fulvestrant has no cytotoxic mechanism; haematological toxicity is not a primary safety concern
Emetogenicity Classification	Minimal to low — administered as intramuscular injection; gastrointestinal symptoms are not a typical feature
Monitoring Items	Liver function tests (LFTs) at baseline and periodically during treatment; bone mineral density (DEXA scan) for patients on long-term therapy; injection site assessment at each visit
Handling Protection	Standard precautions for injectable antineoplastic agents apply; fulvestrant is administered as two 5 mL slow intramuscular injections (total 500 mg). Refer to local hospital pharmacy cytotoxic handling policy for classification

Safety Considerations

Please refer to the SmPC (Samenvatting van de Productkenmerken) for complete safety information. The current Evidence Pack does not contain specific key warnings, contraindications, or drug interaction data for fulvestrant.

The EMA-approved SmPC for Faslodex is available via the EMA medicines database and must be consulted before clinical use for the full risk profile, including hepatic impairment guidance, use in pre-menopausal women (requires concomitant LHRH agonist), thromboembolic risk, and known drug interactions.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Fulvestrant has robust Phase 3 RCT evidence (PALOMA-3, MONALEESA-3, SOLAR-1) confirming its efficacy as a backbone endocrine therapy in HR+/HER2− advanced breast cancer — the principal oestrogen receptor-driven endocrine neoplasm that the TxGNN “multiple endocrine neoplasia” prediction maps to. The evidence level (L1) is the highest achievable, and the mechanism of action (ERα degradation in hormone-driven tumours) is thoroughly validated. The primary barrier to use in the Netherlands is not evidence but access and reimbursement infrastructure.

To proceed, the following is needed:

Confirm the current EMA centralized marketing authorisation status for Faslodex and document the dispensing pathway available to Dutch hospital pharmacists (standard EU supply chain vs. named-patient import)
Retrieve the current EMA SmPC and PIL for fulvestrant to formally complete the safety assessment (key warnings, contraindications, drug-drug interactions) — currently a Blocking data gap in this Evidence Pack
Formally document fulvestrant’s mechanism of action (ERα degradation via SERD pathway) in the Evidence Pack to resolve the current High-severity data gap
Clarify the specific indication scope for any reimbursement application to Zorginstituut Nederland (ZIN): first-line vs. second-line HR+/HER2− advanced breast cancer, and whether combination partners (CDK4/6 inhibitors) are within scope
Conduct a pharmacoeconomic analysis against current Dutch standard-of-care regimens (e.g., palbociclib + letrozole in first line) within the ZIN cost-effectiveness framework
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.